10-Q: Orchestra BioMed Holdings Reports First Quarter 2024 Results, Cites Progress in Clinical Programs

Orchestra BioMed Holdings reported a net loss of $13.5 million for the first quarter of 2024, while highlighting advancements in its BackBeat CNT and Virtue SAB programs.

Summary

• Orchestra BioMed Holdings reported a net loss of $13.5 million for the first quarter of 2024, compared to a net loss of $10.9 million in the same period of 2023.
• The company's total revenue decreased to $620,000 from $1.2 million year-over-year, with partnership revenue declining to $497,000 from $1.0 million.
• Research and development expenses increased to $9.1 million from $8.3 million year-over-year, while selling, general, and administrative expenses rose to $5.9 million from $4.4 million.
• The company's cash and cash equivalents stood at $23.3 million, with marketable securities at $51.7 million as of March 31, 2024.
• Orchestra BioMed anticipates its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2026.
• The company is prioritizing spending on its BackBeat CNT program and has delayed the initiation of the Virtue ISR-US pivotal study pending a restructuring of its agreement with Terumo.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical programs, the increased losses, decreased revenue, and study delays are concerning. The company's cash runway is a positive, but the need for potential future capital raises and the uncertainty around the Terumo agreement are negative factors.

Positives

• The company has commenced enrollment in its BACKBEAT pivotal study.
• The company anticipates its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2026.

Negatives

• The company's net loss increased to $13.5 million in Q1 2024 from $10.9 million in Q1 2023.
• Total revenue decreased by 47% year-over-year.
• Partnership revenue from the Terumo Agreement decreased by 51%.
• The company has delayed the initiation of its Virtue ISR-US pivotal study.
• Research and development expenses increased by 10% year-over-year.
• Selling, general, and administrative expenses increased by 34% year-over-year.

Risks

• The company is subject to risks and uncertainties similar to other biomedical device companies, including uncertainty of clinical trial outcomes and the need for additional funding.
• The company is unlikely to meet certain time-based milestone payments under the Terumo Agreement due to delays in the Virtue SAB program.
• The company is negotiating with Terumo to restructure milestone payments and may not reach a satisfactory agreement, which could adversely impact the Virtue SAB program.
• The company's ability to raise future financing depends on market conditions and the progress of its research and development programs.
• The company's stock price may be volatile due to the large number of shares registered for resale.

Future Outlook

The company anticipates its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2026. The company is prioritizing spending on its BackBeat CNT program and has delayed the initiation of the Virtue ISR-US pivotal study pending a restructuring of its agreement with Terumo.

Management Comments

• Management has concluded that sufficient capital is available to fund its operations and meet cash requirements through the one-year period subsequent to the issuance date of these financial statements.
• Management may consider plans to raise capital beyond the one-year period subsequent to the issuance date of these financial statements through issuance of equity securities, debt securities, and/or additional development and commercialization partnerships for other products within the Company's development pipeline.

Industry Context

The company operates in the highly competitive biomedical device industry, facing competition from larger companies. The company's partnership-enabled business model is designed to mitigate some of the risks associated with developing and commercializing new medical technologies.

Comparison to Industry Standards

• The company's revenue is low compared to established medical device companies, reflecting its early stage of commercialization.
• The increase in R&D spending is typical for companies in the clinical development phase, but the increase in SG&A expenses is higher than some peers.
• The company's cash runway into the second half of 2026 is a positive sign, but the need for additional capital raises is a common challenge for companies in this sector.
• The delay in the Virtue ISR-US pivotal study is a setback, as competitors such as Boston Scientific have recently received FDA approval for similar products.

Related Party Transactions

• The company had transactions and balances with related parties, including investments in Vivasure and Motus GI.

Stakeholder Impact

• Shareholders may be concerned about the increased losses and decreased revenue.
• Employees may be affected by the company's cost-cutting measures and changes in priorities.
• Customers of FreeHold may be affected by changes in product availability.
• Partners such as Medtronic and Terumo may be affected by changes in the company's strategy and timelines.

Next Steps

• The company will continue to prioritize spending on its BackBeat CNT program and the execution of its BACKBEAT pivotal study.
• The company will continue to negotiate with Terumo to restructure the Terumo Agreement.
• The company will continue to evaluate the design for the Virtue ISR-US pivotal study.
• The company will continue to monitor its cash position and may seek additional sources of liquidity.

Key Dates

Keywords

Orchestra BioMed, BackBeat CNT, AVIM therapy, Virtue SAB, hypertension, atherosclerotic artery disease, clinical trials, Medtronic, Terumo, financial results